Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50393 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL50391 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL22005280 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL10034501 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL50689 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL10034502 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL51683 | 1.00 | DRD2 (1.00) | DRD2DRD1HTR1AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL50839 | 0.99 | DRD2 (0.98) | DRD2DRD1HTR1AMEN1LMNA | |
| SCHEMBL242083 | 0.91 | DRD2 (0.83) | DRD2DRD1HTR1A | |
| SCHEMBL50824 | 0.91 | DRD2 (0.83) | DRD2DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400967-B1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H LUNDBECK AS (DK) | 2019-08-14 | — | — | EP | disclosed |
| EP-3009437-A1 | A CATECHOLAMINE DERIVATIVE USEFUL FOR THE TREATMENT OF PARKINSON'S DISEASE | H. Lundbeck A/S (DK) | 2016-04-20 | — | — | EP | disclosed |
| EP-2197883-B1 | Catecholamine derivative useful for the treatment of parkinson's disease | LUNDBECK & CO AS H (DK) | 2015-11-18 | — | — | EP | disclosed |
| EP-2662358-A1 | Catecholamine derivatives and prodrugs thereof | H. Lundbeck A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2012-05-03 | — | — | US | disclosed |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2012-05-03 | — | — | US | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | DRD2 184/4885DRD1 467/4885HTR1A 210/4885 |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | DRD2 184/4885DRD1 467/4885HTR1A 210/4885 |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | PARK7, ACHE, SNCA | DRD2 416/4885DRD1 906/4885HTR1A 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.